[
    [
        {
            "time": "2018-01-01",
            "original_text": "医疗保健：同时明确首家生物类似药为高 荐14股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "生物类似药",
                    "荐股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医疗保健：同时明确首家生物类似药为高 荐14股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "医药行业2018年1月份投资月报:2018的“2+2”医药投资策略",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资月报",
                    "2+2策略"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2018年1月份投资月报:2018的“2+2”医药投资策略",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "医药行业2018年投资策略：正本清源柳暗花明",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "正本清源"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2018年投资策略：正本清源柳暗花明",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "医疗保健：加速仿制药进口替代荐2股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "仿制药",
                    "进口替代",
                    "荐股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医疗保健：加速仿制药进口替代荐2股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "医药行业2018年策略报告:把握政策主线,关注结构性机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "政策主线",
                    "结构性机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2018年策略报告:把握政策主线,关注结构性机会",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "老沙:芳华2018：拒绝一九分化、拒绝韭菜茬！",
            "features": {
                "keywords": [
                    "老沙",
                    "芳华2018",
                    "拒绝分化",
                    "拒绝韭菜"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "老沙:芳华2018：拒绝一九分化、拒绝韭菜茬！",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "机构去年调研1500家A股公司，海康威视连续两年最受机构青睐",
            "features": {
                "keywords": [
                    "机构调研",
                    "A股公司",
                    "海康威视"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "机构去年调研1500家A股公司，海康威视连续两年最受机构青睐",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策落地",
                    "创新药",
                    "仿制药",
                    "医疗服务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]